Addlife AB: Recent Trading Activity and Quarterly Performance
Trading Overview
Stock Performance Addlife (ALIF‑B.ST) closed 2.92 % higher in a 24‑hour period ending 08:34 PM Central Europe on Thursday, 22 October 2026. The current price is approximately SEK 180.7 on major exchanges.
Market Capitalisation and Volume The company’s market cap is SEK 23 billion. Total shares outstanding: 120.1 million. Volume traded in the last 24 hours: SEK 91.7 million.
Historical Context Since the end of the previous month, Addlife shares have risen 13.38 %. The 200‑day simple moving average is SEK 155.21. The 52‑week high was SEK 207.8 on 24 October 2025; the low was SEK 130.2 on 23 March 2026.
Third‑Quarter 2026 Financial Results
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Adjusted EBITA | SEK 298 million | Slightly above analyst expectations |
| Revenue | SEK 2.6 billion | Up ~7 % YoY; ~4 % organic growth + acquisition add‑on |
| Operating Margin | Improved marginally | – |
| Cash Flow from Operations | Increased | – |
| Acquisitions | 6 completed in 2025, 4 planned for Q4 2026 | Enabled higher acquisition rate |
Management emphasised a stronger balance sheet and operational gains that support the planned acquisition activity. Analysts expect modest upward revisions to next‑year EBITA forecasts. SB1 Markets maintains a buy recommendation with a target price, projecting a neutral to mildly positive market reaction.
Comparative Performance of Related Stocks (Last 24 Hours)
| Ticker | % Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Bioarctic (BIOA‑B.ST) | +0.4 % | SEK 301.4 | SEK 26.7 bn | 255.17 |
| Wallenstam‑B (WALL‑B.ST) | –0.64 % | SEK 38.02 | SEK 23.8 bn | 8.18 |
| Bufab (BUFAB.ST) | +0.57 % | SEK 136.6 | SEK 26.7 bn | 38.21 |
| Asker Healthcare (ASKER.ST) | +1.29 % | SEK 71.55 | SEK 26.8 bn | – |
| Tieto (TIETO.HE) | +1.8 % | EUR 19.43 | EUR 2.1 bn | 10.16 |
Bufab: On 23 October 2026, the company presented its latest quarterly results. Analysts now project a moderate rise in earnings per share and revenue expectations, reflecting an upward adjustment from the prior year. Guidance indicates a continuation of this trend for the fiscal year.
Asker Healthcare: On 21 October 2026, the company announced a webcast on 4 November to present its Q3 2026 earnings. The event will feature the CEO and CFO and will be available live and on‑demand.
Company Profile
AddLife AB operates in the life‑sciences tools and services sector, providing products, services, and advisory services to private and public life‑science companies across Sweden, Finland, Denmark, Norway, and internationally. The company is divided into two segments:
Labtech: Supplies analysis instruments, equipment, microscopes, consumables, reagents, and technical services to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point‑of‑care testing, and veterinary diagnostics. The segment also offers training programs, seminars, and advisory services.
Medtech: Delivers medical device products for surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ENT, ostomies, home healthcare, surgical equipment, and laboratory applications.
AddLife AB continues to pursue growth through organic expansion and strategic acquisitions, supported by a robust financial position and a diversified product portfolio.